John Throup

2.9k total citations · 2 hit papers
32 papers, 2.2k citations indexed

About

John Throup is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, John Throup has authored 32 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 14 papers in Immunology and 11 papers in Oncology. Recurrent topics in John Throup's work include Psoriasis: Treatment and Pathogenesis (12 papers), Cytokine Signaling Pathways and Interactions (9 papers) and Bacterial Genetics and Biotechnology (5 papers). John Throup is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (12 papers), Cytokine Signaling Pathways and Interactions (9 papers) and Bacterial Genetics and Biotechnology (5 papers). John Throup collaborates with scholars based in United States, United Kingdom and Canada. John Throup's co-authors include Gordon S.A.B. Stewart, Paul Williams, Simon Swift, Barrie W. Bycroft, Michael K. Winson, Siri Ram Chhabra, George P. C. Salmond, Steve Atkinson, Martin Burnham and Subhashis Banerjee and has published in prestigious journals such as Nature Biotechnology, Biochemistry and Trends in Biochemical Sciences.

In The Last Decade

John Throup

31 papers receiving 2.2k citations

Hit Papers

Deucravacitinib versus pl... 2022 2026 2023 2024 2022 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
  2. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
    2022 173 citations Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
John Throup 1.3k 597 450 317 257 32 2.2k
Daniel W. Martin 1.8k 1.4× 724 1.2× 169 0.4× 221 0.7× 293 1.1× 49 2.7k
Charles R. Dean 977 0.8× 613 1.0× 209 0.5× 159 0.5× 279 1.1× 52 2.0k
Teruko Nakazawa 1.1k 0.8× 491 0.8× 389 0.9× 178 0.6× 111 0.4× 79 2.5k
Mathieu Cellier 715 0.6× 258 0.4× 442 1.0× 356 1.1× 192 0.7× 46 3.0k
Qiuhe Lu 1.7k 1.3× 307 0.5× 789 1.8× 93 0.3× 404 1.6× 31 2.8k
Maren Scharfe 1.3k 1.0× 290 0.5× 149 0.3× 157 0.5× 128 0.5× 34 1.9k
M. Indriati Hood 934 0.7× 263 0.4× 290 0.6× 162 0.5× 279 1.1× 12 2.3k
Elhanan Pinner 1.0k 0.8× 371 0.6× 175 0.4× 315 1.0× 113 0.4× 15 1.9k
Thomas Maier 1.0k 0.8× 255 0.4× 166 0.4× 185 0.6× 241 0.9× 54 2.7k
Nancy J. Phillips 1.1k 0.9× 382 0.6× 319 0.7× 57 0.2× 185 0.7× 75 2.4k

Countries citing papers authored by John Throup

Since Specialization
Citations

This map shows the geographic impact of John Throup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Throup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Throup more than expected).

Fields of papers citing papers by John Throup

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Throup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Throup. The network helps show where John Throup may publish in the future.

Co-authorship network of co-authors of John Throup

This figure shows the co-authorship network connecting the top 25 collaborators of John Throup. A scholar is included among the top collaborators of John Throup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Throup. John Throup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Viader, Andreu, John Throup, Heike J. Wobst, et al.. (2024). JNT-517, a first-in-class SLC6A19 inhibitor for the treatment of phenylketonuria, enhances urinary excretion of phenylalanine in healthy volunteers. Molecular Genetics and Metabolism. 141(4). 108267–108267.
2.
Wobst, Heike J., Giovanni Muncipinto, Andreu Viader, et al.. (2023). A SMALL MOLECULE SLC6A19 INHIBITOR INCREASES URINARY PHENYLALANINE EXCRETION AND REDUCES ITS PATHOGENIC PLASMA ACCUMULATION IN A PHENYLKETONURIA MOUSE MODEL. Molecular Genetics and Metabolism. 138(3). 107502–107502. 4 indexed citations
3.
Strober, Bruce, Diamant Thaçi, Howard Sofen, et al.. (2023). Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary. Immunotherapy. 15(11). 787–797. 2 indexed citations
4.
Armstrong, April W., Melinda Gooderham, Richard B. Warren, et al.. (2022). Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. Journal of the American Academy of Dermatology. 88(1). 29–39. 219 indexed citations breakdown →
5.
Strober, Bruce, Diamant Thaçi, Howard Sofen, et al.. (2022). Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. Journal of the American Academy of Dermatology. 88(1). 40–51. 173 indexed citations breakdown →
6.
Armstrong, April W., Richard B. Warren, Howard Sofen, et al.. (2022). 34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials. Journal of the American Academy of Dermatology. 87(3). AB156–AB156. 2 indexed citations
7.
Chimalakonda, Anjaneya, James R. Burke, Lihong Cheng, et al.. (2021). Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatology and Therapy. 11(5). 1763–1776. 88 indexed citations
8.
Cai, Weiguo, Tarek A. Leil, Leonid Gibiansky, et al.. (2020). Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing. Clinical Pharmacology in Drug Development. 9(6). 689–698. 3 indexed citations
9.
Singhal, Shalabh, Diane E. Shevell, Huadong Sun, et al.. (2020). Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. Clinical Pharmacology in Drug Development. 10(1). 8–21. 1 indexed citations
10.
11.
Chimalakonda, Anjaneya, et al.. (2019). P638 BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects. Journal of Crohn s and Colitis. 13(Supplement_1). S437–S438. 3 indexed citations
12.
Kumar, Sanjay, et al.. (2013). Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma. Frontiers in Pharmacology. 4. 54–54. 10 indexed citations
13.
14.
Throup, John, Francesca Zappacosta, R. Dwayne Lunsford, et al.. (2001). The srhSR Gene Pair from Staphylococcus aureus:  Genomic and Proteomic Approaches to the Identification and Characterization of Gene Function. Biochemistry. 40(34). 10392–10401. 87 indexed citations
15.
Throup, John, Kristin K. Koretke, Alexander P. Bryant, et al.. (2000). A genomic analysis of two‐component signal transduction in Streptococcus pneumoniae. Molecular Microbiology. 35(3). 566–576. 261 indexed citations
16.
Atkinson, Steve, John Throup, Gordon S.A.B. Stewart, & Paul Williams. (1999). A hierarchical quorum‐sensing system in Yersinia pseudotuberculosis is involved in the regulation of motility and clumping. Molecular Microbiology. 33(6). 1267–1277. 142 indexed citations
17.
Fray, Rupert G., John Throup, Mavis Daykin, et al.. (1999). Plants genetically modified to produce N-acylhomoserine lactones communicate with bacteria. Nature Biotechnology. 17(10). 1017–1020. 96 indexed citations
18.
Winson, Michael K., Simon Swift, John Throup, et al.. (1998). Construction and analysis ofluxCDABE-based plasmid sensors for investigatingN-acyl homoserine lactone-mediated quorum sensing. FEMS Microbiology Letters. 163(2). 185–192. 488 indexed citations
19.
Throup, John, Miguel Cámara, Geoffrey S. Briggs, et al.. (1995). Characterisation of the yenI/yenR locus from Yersinia enterocolitica mediating the synthesis of two N‐acylhomoserine lactone signal molecules. Molecular Microbiology. 17(2). 345–356. 125 indexed citations
20.
Swift, Simon, Michael K. Winson, Pan F. Chan, et al.. (1993). A novel strategy for the isolation of luxl homologues: evidence for the widespread distribution of a LuxR:Luxl superfamily in enteric bacteria. Molecular Microbiology. 10(3). 511–520. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel W. Martin Breakdown of academic impact, for papers by Charles R. Dean Breakdown of academic impact, for papers by Teruko Nakazawa Breakdown of academic impact, for papers by Mathieu Cellier Breakdown of academic impact, for papers by Qiuhe Lu Breakdown of academic impact, for papers by Maren Scharfe Breakdown of academic impact, for papers by M. Indriati Hood Breakdown of academic impact, for papers by Elhanan Pinner Breakdown of academic impact, for papers by Thomas Maier Breakdown of academic impact, for papers by Nancy J. Phillips
Rankless by CCL
2026